SNT - General Discussions, page-85

I'd be bloody ecstatic with 53c , I can easily see this stock @ 9c /10c prior to the Phase II SNT 6302 Trial Data release in December then the Results should be all accounts catapult the SP back towards historical averages 18c / 20c.

If the data is promoted in the United States and we are talking a "First in Class Medicine" then that will surely attract Big Pharma Attention?

Usually there is an incumbent or competitor that has to be challenged but with SNT 6302 the road is clear ahead the Market is Wide Open.. NZT